These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37706660)

  • 1. Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2
    Wei Q; Yao K; Yang J; Zhou Q; Liu P; Chen J; Liu H; Lai Y; Cao P
    J Med Chem; 2023 Sep; 66(18):12894-12910. PubMed ID: 37706660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.
    Yang J; Chen J; Chang J; Sun X; Wei Q; Cai X; Cao P
    Cell Commun Signal; 2024 Feb; 22(1):116. PubMed ID: 38347540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
    Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
    Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
    Chen J; Yang J; Sun X; Wang Z; Cheng X; Lu W; Cai X; Hu C; Shen X; Cao P
    Sci Rep; 2017 Nov; 7(1):16458. PubMed ID: 29184081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
    Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
    Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.
    Tawfik HO; Mousa MHA; Zaky MY; El-Dessouki AM; Sharaky M; Abdullah O; El-Hamamsy MH; Al-Karmalawy AA
    Bioorg Chem; 2024 Aug; 149():107483. PubMed ID: 38805913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
    Li Z; Wu X; Jia L; Li J; Zhang R; Tang H; Li Z; Bu H; Shen C
    Bioorg Med Chem Lett; 2020 May; 30(9):127070. PubMed ID: 32143887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
    Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
    Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new IDH2
    Chen X; Wu X; Gao J; Ying H; Dong X; Che J; Shen Z
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000063. PubMed ID: 33184958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic IDH2
    Wang D; Zheng L; Cheng BYL; Sin CF; Li R; Tsui SP; Yi X; Ma ACH; He BL; Leung AYH; Sun X
    Oncogene; 2023 Apr; 42(16):1272-1281. PubMed ID: 36739363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
    Luo LQ; Peng ZY; Liu X; Yu WZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
    Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
    Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
    Che J; Huang F; Zhang M; Xu G; Qu B; Gao J; Chen B; Zhang J; Ying H; Hu Y; Hu X; Zhou Y; Gao A; Li J; Dong X
    Eur J Med Chem; 2020 Oct; 203():112491. PubMed ID: 32679449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.
    Ashraf S; Noguera NI; Di Giandomenico J; Zaza S; Hasan SK; Lo-Coco F
    Ann Hematol; 2013 Oct; 92(10):1319-23. PubMed ID: 23949315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
    Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
    Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
    Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
    J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
    Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
    Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.